Autoimmune Disease Diagnostics Market
Description
Autoimmune Disease Diagnostics Market Summary
The global autoimmune disease diagnostics market size was estimated at USD 6.07 billion in 2025 and is projected to reach USD 9.58 billion by 2033, growing at a CAGR of 5.84% from 2026 to 2033. The increasing prevalence of autoimmune disorders such as type 1 diabetes in newborn babies, coupled with the demand for rapid diagnostics, is the key driver accentuating growth.
In addition, there is an increasing focus on investments and funding for research related to autoimmune diseases, which further propels market growth. Furthermore, developing countries offer untapped opportunities for market expansion, presenting significant growth prospects in the years to come.
The establishment of technological advancements and the expansion of lab automation rates are anticipated to boost market growth. Clinicians are implementing advanced technology to conduct several tests at the same time with faster and more precise results.
Autoimmune diseases are a group of more than 100 chronic, debilitating conditions that affect approximately 3% of the US population. Some of the most common autoimmune diseases include obesity, cardiovascular diseases, type 2 diabetes mellitus, and all cancers. Thus, genetic factors, environmental influences, specific hormones, and susceptibility to certain infections are key contributors to the rising prevalence of autoimmune diseases globally. According to an article published by the National Health Council in September 2024, autoimmune diseases affect approximately 50 million Americans, and women account for 80% of this number. Given the inherent complexity involved in diagnosing these conditions, this figure is likely understated. More concerning is the fact that autoimmune diseases are approaching epidemic proportions, with several studies indicating annual growth rates in the range of 3%-12%.
An increasing rate of novel technological advancements and the corresponding emergence of laboratory automation technologies significantly contribute to market expansion. This trend is driven by the growing adoption of advanced technologies among clinicians, enabling them to conduct a wide range of tests while achieving faster and more accurate results. For instance, in January 2025, Werfen received FDA clearance for Aptiva Antiphospholipid Syndrome (APS) Immunoglobulin G (IgG) and Immunoglobulin M (IgM) Reagents. These assays enhance the accuracy of antiphospholipid syndrome (APS) diagnosis, addressing a significant unmet need in the diagnosis of autoimmune diseases.
In addition, the implementation of government initiatives across economies supports market developments. Work by organizations such as the Autoimmunity Centers of Excellence (ACE), the Cooperative Study Group for Autoimmune Disease Prevention (CSGADP), and the North American Rheumatoid Arthritis Consortium (NARAC) contributes to market growth by creating awareness among patients and healthcare professionals regarding proper diagnosis and treatment protocols.
The involvement of organizations such as the Autoimmunity Centers of Excellence, Cooperative Study Group for Autoimmune Disease Prevention, and North American Rheumatoid Arthritis Consortium in educating patients and healthcare professionals about proper diagnosis and treatment is anticipated to have a positive impact on market dynamics, as it promotes awareness and early intervention in autoimmune diseases. This, in turn, is expected to drive the growth of the autoimmune disease diagnostics market. Besides, favorable government initiatives aimed at increasing access to diagnostic tests, improving disease management and reducing healthcare costs, among other factors, are also expected to boost market growth during the forecast period.
Global Autoimmune Disease Diagnostics Market Report Segmentation
This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global autoimmune disease diagnostics market report based on type, product, test, end use, and region.
The global autoimmune disease diagnostics market size was estimated at USD 6.07 billion in 2025 and is projected to reach USD 9.58 billion by 2033, growing at a CAGR of 5.84% from 2026 to 2033. The increasing prevalence of autoimmune disorders such as type 1 diabetes in newborn babies, coupled with the demand for rapid diagnostics, is the key driver accentuating growth.
In addition, there is an increasing focus on investments and funding for research related to autoimmune diseases, which further propels market growth. Furthermore, developing countries offer untapped opportunities for market expansion, presenting significant growth prospects in the years to come.
The establishment of technological advancements and the expansion of lab automation rates are anticipated to boost market growth. Clinicians are implementing advanced technology to conduct several tests at the same time with faster and more precise results.
Autoimmune diseases are a group of more than 100 chronic, debilitating conditions that affect approximately 3% of the US population. Some of the most common autoimmune diseases include obesity, cardiovascular diseases, type 2 diabetes mellitus, and all cancers. Thus, genetic factors, environmental influences, specific hormones, and susceptibility to certain infections are key contributors to the rising prevalence of autoimmune diseases globally. According to an article published by the National Health Council in September 2024, autoimmune diseases affect approximately 50 million Americans, and women account for 80% of this number. Given the inherent complexity involved in diagnosing these conditions, this figure is likely understated. More concerning is the fact that autoimmune diseases are approaching epidemic proportions, with several studies indicating annual growth rates in the range of 3%-12%.
An increasing rate of novel technological advancements and the corresponding emergence of laboratory automation technologies significantly contribute to market expansion. This trend is driven by the growing adoption of advanced technologies among clinicians, enabling them to conduct a wide range of tests while achieving faster and more accurate results. For instance, in January 2025, Werfen received FDA clearance for Aptiva Antiphospholipid Syndrome (APS) Immunoglobulin G (IgG) and Immunoglobulin M (IgM) Reagents. These assays enhance the accuracy of antiphospholipid syndrome (APS) diagnosis, addressing a significant unmet need in the diagnosis of autoimmune diseases.
In addition, the implementation of government initiatives across economies supports market developments. Work by organizations such as the Autoimmunity Centers of Excellence (ACE), the Cooperative Study Group for Autoimmune Disease Prevention (CSGADP), and the North American Rheumatoid Arthritis Consortium (NARAC) contributes to market growth by creating awareness among patients and healthcare professionals regarding proper diagnosis and treatment protocols.
The involvement of organizations such as the Autoimmunity Centers of Excellence, Cooperative Study Group for Autoimmune Disease Prevention, and North American Rheumatoid Arthritis Consortium in educating patients and healthcare professionals about proper diagnosis and treatment is anticipated to have a positive impact on market dynamics, as it promotes awareness and early intervention in autoimmune diseases. This, in turn, is expected to drive the growth of the autoimmune disease diagnostics market. Besides, favorable government initiatives aimed at increasing access to diagnostic tests, improving disease management and reducing healthcare costs, among other factors, are also expected to boost market growth during the forecast period.
Global Autoimmune Disease Diagnostics Market Report Segmentation
This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global autoimmune disease diagnostics market report based on type, product, test, end use, and region.
- Type Outlook (Revenue, USD Million, 2021 - 2033)
- Systemic autoimmune disease diagnostics
- Rheumatoid arthritis
- Ankylosing spondylitis
- Systemic lupus erythematosus (SLE)
- Others
- Localized autoimmune disease diagnostics
- Multiple sclerosis
- Type 1 diabetes
- Hashimoto's Thyroiditis
- Idiopathic thrombocytopenic purpura
- Others
- Product Outlook (Revenue, USD Million, 2021 - 2033)
- Instruments
- Consumables and Assays
- Test Outlook (Revenue, USD Million, 2021 - 2033)
- Antinuclear antibody tests
- Autoantibody tests
- C-reactive Protein (CRP)
- Complete blood count (CBC)
- Urinalysis
- Others
- End Use Outlook (Revenue, USD Million, 2021 - 2033)
- Hospitals
- Diagnostic centers
- Others
- Regional Outlook (Revenue, USD Million, 2021 - 2033)
- North America
- U.S.
- Canada
- Mexico
- Europe
- UK
- Germany
- France
- Italy
- Spain
- Sweden
- Norway
- Denmark
- Asia Pacific
- Japan
- China
- India
- Australia
- Thailand
- South Korea
- Latin America
- Brazil
- Argentina
- Middle East and Africa (MEA)
- South Africa
- Saudi Arabia
- UAE
- Kuwait
Table of Contents
129 Pages
- Chapter 1. Methodology and Scope
- 1.1. Market Segmentation and Scope
- 1.1.1. Product
- 1.1.2. Distribution Channel
- 1.1.3. End Use
- 1.1.4. Regional scope
- 1.1.5. Estimates and forecast timeline
- 1.2. Market Definitions
- 1.3. Research Methodology
- 1.4. Information Procurement
- 1.4.1. Purchased Database
- 1.4.2. GVR’s Internal Database
- 1.5. Details of primary research
- 1.5.1. Data for primary interviews in North America
- 1.5.2. Data for primary interviews in Europe
- 1.5.3. Data for primary interviews in Asia Pacific
- 1.5.4. Data for primary interviews in Latin America
- 1.5.5. Data for Primary interviews in MEA
- 1.6. Market Formulation & Validation
- 1.7. Model Details
- 1.7.1. Commodity flow analysis (Model 1)
- 1.7.1.1. Approach 1: Commodity flow approach
- 1.7.2. Volume price analysis (Model 2)
- 1.7.2.1. Approach 2: Volume price analysis
- 1.8. Research Scope and Assumptions
- 1.8.1. List of Secondary Sources
- 1.8.2. List of Primary Sources
- 1.8.3. Objectives
- Chapter 2. Executive Summary
- 2.1. Market Outlook
- 2.2. Segment Outlook
- 2.3. Competitive Insights
- Chapter 3. Oral Care Market Variables, Trends, & Scope
- 3.1. Market Lineage Outlook
- 3.1.1. Parent Market Outlook
- 3.1.2. Related/Ancillary Market Outlook
- 3.2. Market Dynamics
- 3.2.1. Market Drivers Analysis
- 3.2.1.1. Growing prevalence of dental diseases
- 3.2.1.2. Development of technologically advanced products
- 3.2.1.3. Growing number of dentists across globe
- 3.2.2. Market Restraints Analysis
- 3.2.2.1. Adverse effects of products
- 3.2.2.2. Limited product penetration of new-age products in developing countries
- 3.2.3. Market Opportunity Analysis
- 3.2.3.1. Growing awareness of oral hygiene
- 3.2.3.2. Shift toward natural and sustainable products
- 3.2.4. Market Challenge Analysis
- 3.2.4.1. High cost of advanced dental treatments
- 3.2.4.2. Limited access to dental care in rural areas
- 3.3. Oral Care Market Analysis Tools
- 3.3.1. Porter’s Analysis
- 3.3.1.1. Bargaining power of the suppliers
- 3.3.1.2. Bargaining power of the buyers
- 3.3.1.3. Threats of substitution
- 3.3.1.4. Threats from new entrants
- 3.3.1.5. Competitive rivalry
- 3.3.2. PESTEL Analysis
- 3.3.2.1. Political landscape
- 3.3.2.2. Economic and Social landscape
- 3.3.2.3. Technological landscape
- 3.3.2.4. Environmental landscape
- 3.3.2.5. Legal landscape
- Chapter 4. Oral Care Market: Product Estimates & Trend Analysis
- 4.1. Segment Dashboard
- 4.2. Global Oral Care Market: Product Movement Analysis, 2025 & 2033 (USD Million)
- 4.3. Global Oral Care Market Size & Trend Analysis, by Product, 2021 to 2033 (USD Million)
- 4.4. Toothbrush
- 4.4.1. Toothbrush market estimates and forecasts, 2021 - 2033 (USD Million)
- 4.4.2. Manual toothbrush
- 4.4.2.1. Manual toothbrush market, 2021 - 2033 (USD Million)
- 4.4.3. Electric toothbrush
- 4.4.3.1. Electric toothbrush market, 2021 - 2033 (USD Million)
- 4.4.4. Battery-powered toothbrush
- 4.4.4.1. Battery-powered toothbrush market, 2021 - 2033 (USD Million)
- 4.4.5. Others
- 4.4.5.1. Others market, 2021 - 2033 (USD Million)
- 4.5. Toothpaste
- 4.5.1. Toothpaste market estimates and forecasts, 2021 - 2033 (USD Million)
- 4.5.2. Gel toothpaste
- 4.5.2.1. Gel toothpaste market, 2021 - 2033 (USD Million)
- 4.5.3. Polish toothpaste
- 4.5.3.1. Polish toothpaste market, 2021 - 2033 (USD Million)
- 4.5.4. Paste toothpaste
- 4.5.4.1. Paste toothpaste market, 2021 - 2033 (USD Million)
- 4.5.5. Powder toothpaste
- 4.5.5.1. Powder toothpaste market, 2021 - 2033 (USD Million)
- 4.6. Mouthwash/Rinse
- 4.6.1. Mouthwash/rinse market estimates and forecasts, 2021 - 2033 (USD Million)
- 4.6.2. Medicated mouthwash/rinse
- 4.6.2.1. Medicated mouthwash/rinse market estimates and forecasts, 2021 - 2033 (USD Million)
- 4.6.3. Non-medicated mouthwash/rinse
- 4.6.3.1. Non-medicated mouthwash/rinse market estimates and forecasts, 2021 - 2033 (USD Million)
- 4.7. Denture products
- 4.7.1. Denture product market estimates and forecasts, 2021 - 2033 (USD Million)
- 4.7.2. Cleaners
- 4.7.2.1. Cleaners market estimates and forecasts, 2021 - 2033 (USD Million)
- 4.7.3. Fixatives
- 4.7.3.1. Fixatives market estimates and forecasts, 2021 - 2033 (USD Million)
- 4.7.4. Others
- 4.7.4.1. Other denture products market estimates and forecasts, 2021 - 2033 (USD Million)
- 4.8. Dental accessories
- 4.8.1. Dental accessories market estimates and forecasts, 2021 - 2033 (USD Million)
- 4.8.2. Cosmetic whitening products
- 4.8.2.1. Cosmetic whitening products market estimates and forecasts, 2021 - 2033 (USD Million)
- 4.8.3. Fresh breath dental chewing gum
- 4.8.3.1. Fresh breath dental chewing gum market estimates and forecasts, 2021 - 2033 (USD Million)
- 4.8.4. Tongue scrappers
- 4.8.4.1. Tongue scrapers market estimates and forecasts, 2021 - 2033 (USD Million)
- 4.8.5. Fresh breath strips
- 4.8.5.1. Fresh breath strips market estimates and forecasts, 2021 - 2033 (USD Million)
- 4.8.6. Others
- 4.8.6.1. Others market estimates and forecasts, 2021 - 2033 (USD Million)
- 4.8.6.2. Oral Irrigators
- 4.8.6.2.1. Oral irrigators market estimates and forecasts, 2021 - 2033 (USD Million)
- 4.8.6.2.2. Countertop
- 4.8.6.2.2.1. Countertop market estimates and forecasts, 2021 - 2033 (USD Million)
- 4.8.6.2.3. Cordless
- 4.8.6.2.3.1. Cordless market estimates and forecasts, 2021 - 2033 (USD Million)
- 4.8.6.3. Mouth freshener sprays
- 4.8.6.3.1. Mouth freshener sprays market estimates and forecasts, 2021 - 2033 (USD Million)
- Chapter 5. Oral Care Market: Distribution Channel Estimates & Trend Analysis
- 5.1. Segment Dashboard
- 5.2. Global Oral Care Market: Distribution Channel Movement Analysis, 2025 & 2033 (USD Million)
- 5.3. Global Oral Care Market Size & Trend Analysis, by Distribution Channel 2021 to 2033 (USD Million)
- 5.4. Supermarkets/hypermarkets
- 5.4.1. Supermarkets/hypermarkets market estimates and forecasts, 2021 - 2033 (USD Million)
- 5.5. Convenience stores
- 5.5.1. Convenience stores market estimates and forecasts, 2021 - 2033 (USD Million)
- 5.6. Online retail stores
- 5.6.1. Online retail stores market estimates and forecasts, 2021 - 2033 (USD Million)
- 5.7. Pharmacy and drug stores
- 5.7.1. Pharmacy and drug stores market estimates and forecasts, 2021 - 2033 (USD Million)
- Chapter 6. Oral Care Market: Regional Estimates & Trend Analysis by Product and Distribution Channel
- 6.1. Regional Dashboard
- 6.2. Market Size and Trend Analysis, 2021 to 2033
- 6.3. North America
- 6.3.1. North America oral care market estimates and forecasts, 2021 - 2033 (USD Million)
- 6.3.2. U.S.
- 6.3.2.1. Key country dynamics
- 6.3.2.2. Competitive scenario
- 6.3.2.3. Regulatory framework
- 6.3.2.4. Reimbursement scenario
- 6.3.2.5. U.S. oral care market estimates and forecasts, 2021 - 2033 (USD Million)
- 6.3.3. Canada
- 6.3.3.1. Key country dynamics
- 6.3.3.2. Competitive scenario
- 6.3.3.3. Regulatory framework
- 6.3.3.4. Reimbursement scenario
- 6.3.3.5. Canada oral care market estimates and forecasts, 2021 - 2033 (USD Million)
- 6.3.4. Mexico
- 6.3.4.1. Key country dynamics
- 6.3.4.2. Competitive scenario
- 6.3.4.3. Regulatory framework
- 6.3.4.4. Reimbursement scenario
- 6.3.4.5. Mexico oral care market estimates and forecasts, 2021 - 2033 (USD Million)
- 6.4. Europe
- 6.4.1. Europe oral care market estimates and forecasts, 2021 - 2033 (USD Million)
- 6.4.2. UK
- 6.4.2.1. Key country dynamics
- 6.4.2.2. Competitive scenario
- 6.4.2.3. Regulatory framework
- 6.4.2.4. Reimbursement scenario
- 6.4.2.5. UK oral care market estimates and forecasts, 2021 - 2033 (USD Million)
- 6.4.3. Germany
- 6.4.3.1. Key country dynamics
- 6.4.3.2. Competitive scenario
- 6.4.3.3. Regulatory framework
- 6.4.3.4. Reimbursement scenario
- 6.4.3.5. Germany oral care market estimates and forecasts, 2021 - 2033 (USD Million)
- 6.4.4. France
- 6.4.4.1. Key country dynamics
- 6.4.4.2. Competitive scenario
- 6.4.4.3. Regulatory framework
- 6.4.4.4. Reimbursement scenario
- 6.4.4.5. France oral care market estimates and forecasts, 2021 - 2033 (USD Million)
- 6.4.5. Italy
- 6.4.5.1. Key country dynamics
- 6.4.5.2. Competitive scenario
- 6.4.5.3. Regulatory framework
- 6.4.5.4. Reimbursement scenario
- 6.4.5.5. Italy oral care market estimates and forecasts, 2021 - 2033 (USD Million)
- 6.4.6. Spain
- 6.4.6.1. Key country dynamics
- 6.4.6.2. Competitive scenario
- 6.4.6.3. Regulatory framework
- 6.4.6.4. Reimbursement scenario
- 6.4.6.5. Spain oral care market estimates and forecasts, 2021 - 2033 (USD Million)
- 6.4.7. Sweden
- 6.4.7.1. Key country dynamics
- 6.4.7.2. Competitive scenario
- 6.4.7.3. Regulatory framework
- 6.4.7.4. Reimbursement scenario
- 6.4.7.5. Sweden oral care market estimates and forecasts, 2021 - 2033 (USD Million)
- 6.4.8. Denmark
- 6.4.8.1. Key country dynamics
- 6.4.8.2. Competitive scenario
- 6.4.8.3. Regulatory framework
- 6.4.8.4. Reimbursement scenario
- 6.4.8.5. Denmark oral care market estimates and forecasts, 2021 - 2033 (USD Million)
- 6.4.9. Norway
- 6.4.9.1. Key country dynamics
- 6.4.9.2. Competitive scenario
- 6.4.9.3. Regulatory framework
- 6.4.9.4. Reimbursement scenario
- 6.4.9.5. Norway oral care market estimates and forecasts, 2021 - 2033 (USD Million)
- 6.5. Asia Pacific
- 6.5.1. Asia Pacific oral care market estimates and forecasts, 2021 - 2033 (USD Million)
- 6.5.2. China
- 6.5.2.1. Key country dynamics
- 6.5.2.2. Competitive scenario
- 6.5.2.3. Regulatory framework
- 6.5.2.4. Reimbursement scenario
- 6.5.2.5. China oral care market estimates and forecasts, 2021 - 2033 (USD Million)
- 6.5.3. Japan
- 6.5.3.1. Key country dynamics
- 6.5.3.2. Competitive scenario
- 6.5.3.3. Regulatory framework
- 6.5.3.4. Reimbursement scenario
- 6.5.3.5. Japan oral care market estimates and forecasts, 2021 - 2033 (USD Million)
- 6.5.4. India
- 6.5.4.1. Key country dynamics
- 6.5.4.2. Competitive scenario
- 6.5.4.3. Regulatory framework
- 6.5.4.4. Reimbursement scenario
- 6.5.4.5. India oral care market estimates and forecasts, 2021 - 2033 (USD Million)
- 6.5.5. South Korea
- 6.5.5.1. Key country dynamics
- 6.5.5.2. Competitive scenario
- 6.5.5.3. Regulatory framework
- 6.5.5.4. Reimbursement scenario
- 6.5.5.5. South Korea oral care market estimates and forecasts, 2021 - 2033 (USD Million)
- 6.5.6. Australia
- 6.5.6.1. Key country dynamics
- 6.5.6.2. Competitive scenario
- 6.5.6.3. Regulatory framework
- 6.5.6.4. Reimbursement scenario
- 6.5.6.5. Australia oral care market estimates and forecasts, 2021 - 2033 (USD Million)
- 6.5.7. Thailand
- 6.5.7.1. Key country dynamics
- 6.5.7.2. Competitive scenario
- 6.5.7.3. Regulatory framework
- 6.5.7.4. Reimbursement scenario
- 6.5.7.5. Thailand oral care market estimates and forecasts, 2021 - 2033 (USD Million)
- 6.6. Latin America
- 6.6.1. Latin America oral care market estimates and forecasts, 2021 - 2033 (USD Million)
- 6.6.2. Brazil
- 6.6.2.1. Key country dynamics
- 6.6.2.2. Competitive scenario
- 6.6.2.3. Regulatory framework
- 6.6.2.4. Reimbursement scenario
- 6.6.2.5. Brazil oral care market estimates and forecasts, 2021 - 2033 (USD Million)
- 6.6.3. Argentina
- 6.6.3.1. Key country dynamics
- 6.6.3.2. Competitive scenario
- 6.6.3.3. Regulatory framework
- 6.6.3.4. Reimbursement scenario
- 6.6.3.5. Argentina oral care market estimates and forecasts, 2021 - 2033 (USD Million)
- 6.7. Middle East and Africa
- 6.7.1. Middle East and Africa oral care market estimates and forecasts, 2021 - 2033 (USD Million)
- 6.7.2. South Africa
- 6.7.2.1. Key country dynamics
- 6.7.2.2. Competitive scenario
- 6.7.2.3. Regulatory framework
- 6.7.2.4. Reimbursement scenario
- 6.7.2.5. South Africa oral care market estimates and forecasts, 2021 - 2033 (USD Million)
- 6.7.3. Saudi Arabia
- 6.7.3.1. Key country dynamics
- 6.7.3.2. Competitive scenario
- 6.7.3.3. Regulatory framework
- 6.7.3.4. Reimbursement scenario
- 6.7.3.5. Saudi Arabia oral care market estimates and forecasts, 2021 - 2033 (USD Million)
- 6.7.4. UAE
- 6.7.4.1. Key country dynamics
- 6.7.4.2. Competitive scenario
- 6.7.4.3. Regulatory framework
- 6.7.4.4. Reimbursement scenario
- 6.7.4.5. UAE oral care market estimates and forecasts, 2021 - 2033 (USD Million)
- 6.7.5. Kuwait
- 6.7.5.1. Key country dynamics
- 6.7.5.2. Competitive scenario
- 6.7.5.3. Regulatory framework
- 6.7.5.4. Reimbursement scenario
- 6.7.5.5. Kuwait oral care market estimates and forecasts, 2021 - 2033 (USD Million)
- Chapter 7. Competitive Landscape
- 7.1. Recent Developments & Impact Analysis by Key Market Participants
- 7.2. Company Categorization
- 7.3. Company Market Share Analysis, 2025
- 7.4. Company Heat Map Analysis
- 7.5. Strategy Mapping
- 7.5.1. Expansion
- 7.5.2. Mergers & Acquisition
- 7.5.3. Partnerships & Collaborations
- 7.5.4. New Product Launches
- 7.5.5. Research And Development
- 7.5.6. Company Profiles
- 7.5.7. Colgate-Palmolive Company
- 7.5.7.1. Company overview
- 7.5.7.2. Financial performance
- 7.5.7.3. Product Benchmarking
- 7.5.7.4. Strategic initiatives
- 7.5.8. GSK plc
- 7.5.8.1. Company overview
- 7.5.8.2. Financial performance
- 7.5.8.3. Product Benchmarking
- 7.5.8.4. Strategic initiatives
- 7.5.9. Johnson & Johnson
- 7.5.9.1. Company overview
- 7.5.9.2. Financial performance
- 7.5.9.3. Product Benchmarking
- 7.5.9.4. Strategic initiatives
- 7.5.10. Church & Dwight Co., Inc.
- 7.5.10.1. Company overview
- 7.5.10.2. Financial performance
- 7.5.10.3. Product Benchmarking
- 7.5.10.4. Strategic initiatives
- 7.5.11. Procter & Gamble
- 7.5.11.1. Company overview
- 7.5.11.2. Financial performance
- 7.5.11.3. Product Benchmarking
- 7.5.11.4. Strategic initiatives
- 7.5.12. Unilever
- 7.5.12.1. Company overview
- 7.5.12.2. Financial performance
- 7.5.12.3. Product Benchmarking
- 7.5.12.4. Strategic initiatives
- 7.5.13. GC America Inc.
- 7.5.13.1. Company overview
- 7.5.13.2. Financial performance
- 7.5.13.3. Product Benchmarking
- 7.5.13.4. Strategic initiatives
- 7.5.14. Lion Corporation
- 7.5.14.1. Company overview
- 7.5.14.2. Financial performance
- 7.5.14.3. Product Benchmarking
- 7.5.14.4. Strategic initiatives
- 7.5.15. Sunstar Suisse S.A.
- 7.5.15.1. Company overview
- 7.5.15.2. Financial performance
- 7.5.15.3. Product Benchmarking
- 7.5.15.4. Strategic initiatives
- 7.5.16. Ivoclar Vivadent
- 7.5.16.1. Company overview
- 7.5.16.2. Financial performance
- 7.5.16.3. Product Benchmarking
- 7.5.16.4. Strategic initiatives
- 7.5.17. Solventum
- 7.5.17.1. Company overview
- 7.5.17.2. Financial performance
- 7.5.17.3. Product Benchmarking
- 7.5.17.4. Strategic initiatives
- 7.5.18. Koninklijke Philips N.V.
- 7.5.18.1. Company overview
- 7.5.18.2. Financial performance
- 7.5.18.3. Product Benchmarking
- 7.5.18.4. Strategic initiatives
- 7.5.19. FOREO
- 7.5.19.1. Company overview
- 7.5.19.2. Financial performance
- 7.5.19.3. Product Benchmarking
- 7.5.19.4. Strategic initiatives
- 7.5.20. Jordan
- 7.5.20.1. Company overview
- 7.5.20.2. Financial performance
- 7.5.20.3. Product Benchmarking
- 7.5.20.4. Strategic initiatives
- 7.5.21. Haleon Group of Companies
- 7.5.21.1. Company overview
- 7.5.21.2. Financial performance
- 7.5.21.3. Product Benchmarking
- 7.5.21.4. Strategic initiatives
- 7.5.22. BURST Oral Care
- 7.5.22.1. Company overview
- 7.5.22.2. Financial performance
- 7.5.22.3. Product Benchmarking
- 7.5.22.4. Strategic initiatives
- 7.5.23. Hismile Pty Ltd.
- 7.5.23.1. Company overview
- 7.5.23.2. Financial performance
- 7.5.23.3. Product Benchmarking
- 7.5.23.4. Strategic initiatives
- 7.5.24. Perrigo Company plc
- 7.5.24.1. Company overview
- 7.5.24.2. Financial performance
- 7.5.24.3. Product Benchmarking
- 7.5.24.4. Strategic initiatives
- 7.5.25. Salt Oral Care
- 7.5.25.1. Company overview
- 7.5.25.2. Financial performance
- 7.5.25.3. Product Benchmarking
- 7.5.25.4. Strategic initiatives
- 7.5.26. Oracura
- 7.5.26.1. Company overview
- 7.5.26.2. Financial performance
- 7.5.26.3. Product Benchmarking
- 7.5.26.4. Strategic initiatives
- 7.5.27. STIM
- 7.5.27.1. Company overview
- 7.5.27.2. Financial performance
- 7.5.27.3. Product Benchmarking
- 7.5.27.4. Strategic initiatives
- 7.5.28. Glidewell
- 7.5.28.1. Company overview
- 7.5.28.2. Financial performance
- 7.5.28.3. Product Benchmarking
- 7.5.28.4. Strategic initiatives
- 7.5.29. Panasonic Industry
- 7.5.29.1. Company overview
- 7.5.29.2. Financial performance
- 7.5.29.3. Product Benchmarking
- 7.5.29.4. Strategic initiatives
- 7.5.30. Great Gums
- 7.5.30.1. Company overview
- 7.5.30.2. Financial performance
- 7.5.30.3. Product Benchmarking
- 7.5.30.4. Strategic initiatives
- 7.5.31. Ultradent Products Inc.
- 7.5.31.1. Company overview
- 7.5.31.2. Financial performance
- 7.5.31.3. Product Benchmarking
- 7.5.31.4. Strategic initiatives
- 7.5.32. VITA Zahnfabrik
- 7.5.32.1. Company overview
- 7.5.32.2. Financial performance
- 7.5.32.3. Product Benchmarking
- 7.5.32.4. Strategic initiatives
- 7.5.33. Avadent
- 7.5.33.1. Company overview
- 7.5.33.2. Financial performance
- 7.5.33.3. Product Benchmarking
- 7.5.33.4. Strategic initiatives
- 7.5.34. BISCO Inc.
- 7.5.34.1. Company overview
- 7.5.34.2. Financial performance
- 7.5.34.3. Product Benchmarking
- 7.5.34.4. Strategic initiatives
- 7.5.35. Kuraray America, Inc
- 7.5.35.1. Company overview
- 7.5.35.2. Financial performance
- 7.5.35.3. Product Benchmarking
- 7.5.35.4. Strategic initiatives
- 7.5.36. Prestige Consumer Healthcare Inc
- 7.5.36.1. Company overview
- 7.5.36.2. Financial performance
- 7.5.36.3. Product Benchmarking
- 7.5.36.4. Strategic initiatives
- 7.5.37. Tokuyama Dental Corporation
- 7.5.37.1. Company overview
- 7.5.37.2. Financial performance
- 7.5.37.3. Product Benchmarking
- 7.5.37.4. Strategic initiatives
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
